Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart
1 Month : From Jun 2019 to Jul 2019
By Stephen Nakrosis
Shares of Bristol-Myers Squibb Co. (BMY) and Celgene Corp. (CELG) are both in the red in Monday's market, following news their planned merger would be delayed due to antitrust concerns.
At 2:51 p.m. ET, Bristol-Myers Squibb shares had lost 7.4%, to trade at $45.69. Volume was heavier than usual, with over 29.1 million shares trading, above the 65-day average volume of some 14.6 million. Celgene shares had lost 5.34%, trading at $93.63. That stock's volume was also higher than usual with over 7.2 million shares trading, above its 65-day average volume of some 6.6 million.
The $74 billion merger faces delays as the companies work to sell Celgene's anti-inflammatory drug, Otzela, in an effort to address concerns raised by antitrust regulators.
--Write to Stephen Nakrosis at email@example.com
(END) Dow Jones Newswires
June 24, 2019 15:15 ET (19:15 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.